EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs), given their low molecular weight, may be able to reach a higher concentration in brain tissues. Various reports and small studies ...

2024 年 12 月 6 日 - 8 日，欧洲肿瘤内科学会亚洲年会（ESMO Asia）将在新加坡盛大召开。本届会议将汇聚全球专家学者，集中展示和讨论肿瘤学领域的最新科学和临床进展，为肿瘤领域带来一场学术盛宴。此次会议中，「Dato-DXd ...

一系列证据表明钠葡萄糖共转运蛋白2抑制剂（SGLT-2i）可以护肾保心，对慢性肾脏病（CKD）有良好的治疗作用，即延缓估算肾小球滤过率（eGFR）下降、降低蛋白尿及全因死亡风险。那么，除了这些获益外，SGLT-2i对肾脏还有哪些益处呢？2024年10 ...

The advancement of EGFR inhibitors for cancer therapy has moved rapidly in the broad context of oncology therapeutics. The fact that four new EGFR inhibitors (gefitinib, cetuximab, erlotinib ...

colorectal (colon) cancer; epidermal growth factor receptor (EGFR); RAS; liquid biopsy; rechallenge; cetuximab; RAS; ...

在国家自然科学基金项目（批准号：82072784、82072785、82273304、82303437）等资助下，复旦大学附属华山医院毛颖教授、花玮教授和迟喻丹研究员团队在免疫逃逸参与肺癌脑转移靶向治疗耐药研究方面取得进展。研究成果以“通过CTLA4 ...

Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...

China’s drug regulator approved Alpha Biopharma Ltd.’s EGFR tyrosine kinase inhibitor (TKI), Zorifer (zorifertinib hydrochloride tablets; AZD-3759), as a first-line treatment for EGFR-mutated ...

SOS1 is a guanine nucleotide exchange factor (GEF) that activates KRAS, and recent preclinical studies have demonstrated that combining KRAS and EGFR inhibitors with SOS1 inhibitors can overcome ...